For the year ending 2025-12-31, PRME made $4,632K in revenue. -$201,142K in net income. Net profit margin of -4342.44%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Collaboration revenue | 4,632 | 1,609 | ||
| Research and development | 160,636 | 155,289 | ||
| General and administrative | 52,346 | 50,161 | ||
| Total operating expenses | 212,982 | 205,450 | ||
| Loss from operations | -208,350 | -202,467 | ||
| Interest income | 4,149 | 3,522 | ||
| Accretion (amortization) of investments | 2,479 | 3,507 | ||
| Change in fair value of short-term investment related party | 432 | -485 | ||
| Other income, net | 148 | 41 | ||
| Total other income, net | 7,208 | 6,585 | ||
| Net loss before income taxes | - | -195,882 | ||
| Net loss attributable to common stockholders, basic | -201,142 | -195,882 | ||
| Net loss attributable to common stockholders, diluted | - | -195,882 | ||
| Basic EPS | -1.35 | -1.65 | ||
| Diluted EPS | -1.35 | -1.65 | ||
| Basic Average Shares | 148,758,527 | 118,600,381 | ||
| Diluted Average Shares | 148,758,527 | 118,600,381 | ||
Prime Medicine, Inc. (PRME)
Prime Medicine, Inc. (PRME)